Featured Service
Fast, Reliable Gene‑to‑Clinic Development
Bring your biologic program to life with an end‑to‑end CRADS platform
View service
Blog
Blog
Research, industry perspectives, and practical know-how from Vimta's scientists and regulatory experts.
Uncategorized
This is a new blog post
This is a new blog post this is the paragral
Investor News
This is the H2 Heading for the Blog Post This is the first paragraph of the blog post and this is where we have to study the font sizes, spacing and gap between each line in order to see if there is rhythm and perfection in the post. In order to see if the right […]
The revised ICH M10 reshapes how sponsors validate bioanalytical methods for regulatory submissions. Here's what CROs — and their sponsor partners — need to adjust in 2026.
Latest
Description post description to provide excerpt for users. The intent is to enhance click rate.
Uncategorized
Why CMC Readiness Makes or Breaks Your IND Filing
CMC gaps remain the leading cause of FDA clinical hold letters. We break down the five most common CMC red flags we see from first-time IND sponsors.
EMI/EMC compliance for medical electronics is no longer a final-stage checkbox. Design-phase pre-compliance testing cuts certification timelines by 30–40%.
News wrothy
Welcome to new blog section to connect with stakeholders, well wishers and industry.
Products destined for Zone IVb markets face specific humidity and temperature stress requirements. A checklist for protocol design and storage chamber planning.
The amended FSSAI regulations tighten limits on pesticide residues, heavy metals, and mycotoxins. Labs and food brands both need to recalibrate their monitoring.
Transfer of bioanalytical methods across labs carries hidden risk. We lay out the decision tree for bridging studies vs. full revalidation under the new ICH framework.
